Background: Reductions in the dose intensity (DI) of adjuvant anthracycline based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain.
Patients and methods: Women with stage I-II breast cancer treated with adjuvant adriamycin and cyclophosphamide (AC) from 1990-1995 were identified in a provincial breast cancer database. Cases were classified into 4 cohorts 1: all cycles delivered at full dose and on time 2: one single dose reduction or dose delay 3: >1 dose reduction or dose delay 4: <2 cycles of chemotherapy delivered.
Results: 484 eligible cases were identified (cohort 1: n = 268 2: n= 88 3: n= 89 4: n= 39). Slight imbalances in lymph node status (p=0.05) and adjuvant hormonal therapy (p=0.05) were observed between the cohorts. 55% (267/484) of the patients had node-positive disease and 33% (158/484) were ER+. 45% of cases had a reduction in DI. With a median follow-up of 9.6 years, there were no significant differences in relapse-free survival (p=0.94), breast cancer-specific survival (p=0.87) or overall survival (p=0.86) between the 4 cohorts. Outcomes were independent of hormone receptor status.
Conclusions: Although toxicity related reductions in the DI of adjuvant AC chemotherapy for early stage breast cancer are common, they did not appear to significantly impact on clinical outcomes in this population-based cohort of women with stage I-II breast cancers.
Further information:
Related posts:
- Risk of breast cancer among daughters of mothers with diabetes: a population-based cohort study
- Full dose intraoperative radiotherapy with electrons (ELIOT) during breast conserving surgery: Experience with 1246 cases
- A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: An update
- PTEN breast cancer susceptibility: a matter of dose
- Does neoadjuvant chemotherapy increase breast conservation in operable breast cancer: an Egyptian experience
Posted in